OMERS ADMINISTRATION Corp Invests $404,000 in Pediatrix Medical Group, Inc. $MD

Key Points

• OMERS ADMINISTRATION Corp has made a new investment of approximately $404,000 in Pediatrix Medical Group by acquiring 27,900 shares of the company's stock in the first quarter.
• Analysts have given Pediatrix Medical Group a Moderate Buy rating with a consensus price target of $16.75, reflecting recent positive adjustments in price targets from firms like UBS Group and Macquarie.
• Pediatrix Medical Group reported an EPS of $0.53 for the last quarter, exceeding expectations, while also noting a 7.1% decline in revenue compared to the previous year.

OMERS ADMINISTRATION Corp purchased a new stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 27,900 shares of the company's stock, valued at approximately $404,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Pediatrix Medical Group by 218.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,445 shares of the company's stock worth $98,000 after purchasing an additional 5,104 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Pediatrix Medical Group by 9.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 77,393 shares of the company's stock valued at $1,016,000 after acquiring an additional 6,753 shares during the period. Northern Trust Corp boosted its holdings in Pediatrix Medical Group by 18.0% during the 4th quarter. Northern Trust Corp now owns 966,347 shares of the company's stock valued at $12,678,000 after acquiring an additional 147,522 shares during the period. BNP Paribas Financial Markets boosted its holdings in Pediatrix Medical Group by 87.8% during the 4th quarter. BNP Paribas Financial Markets now owns 34,776 shares of the company's stock valued at $456,000 after acquiring an additional 16,256 shares during the period. Finally, Bayesian Capital Management LP purchased a new stake in Pediatrix Medical Group during the 4th quarter valued at about $190,000. 97.71% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MD has been the subject of several analyst reports. Leerink Partners increased their target price on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a "market perform" rating in a report on Friday. UBS Group increased their target price on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research report on Thursday, August 14th. Finally, Zacks Research raised Pediatrix Medical Group to a "strong-buy" rating in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $16.79.

Pediatrix Medical Group Stock Down 0.2%

MD traded down $0.04 during trading on Tuesday, hitting $16.92. 109,184 shares of the company's stock traded hands, compared to its average volume of 756,110. The company's 50 day simple moving average is $14.51 and its two-hundred day simple moving average is $14.12. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70. Pediatrix Medical Group, Inc. has a 12-month low of $10.29 and a 12-month high of $17.67. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 13.16 and a beta of 1.29.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.42 by $0.11. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The business had revenue of $468.84 million for the quarter, compared to the consensus estimate of $464.37 million. During the same period last year, the business posted $0.34 EPS. The company's revenue was down 7.1% compared to the same quarter last year. Analysts predict that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.